RLYB has a diverse pipeline targeting rare diseases. Recently, it announced proof of concept data. The company has a decent cash runway and looks interesting. Lead asset RLYB212 is an Anti-HPA-1a ...
Tyra Biosciences (TYRA) develops precision medicines using fibroblast growth factor receptor (FGFR) biology. These are small molecules. Lead asset is TYRA-300, the first oral FGFR3-selective inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results